Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study

References

• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S13–S27.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF diabetes atlas - 8th edition. 2017. [cited 2019 14 March]. Available from: http://diabetesatlas.org/resources/2017-atlas.html.Epublished.
   Google Scholar
• Goto A, Noda M, Inoue M, et al. Increasing number of people with diabetes in Japan: is this trend real? Intern Med. 2016;55(14):1827–1830.
   PubMed Web of Science ®Google Scholar
• Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol. 2012;8(4):228–236.
   Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–787.
   PubMed Web of Science ®Google Scholar
• Aljuaid MO, Almutairi AM, Assiri MA, et al. Diabetes-related distress assessment among type 2 diabetes patients. J Diabetes Res. 2018;2018:7328128.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251.
   PubMed Web of Science ®Google Scholar
• Nanayakkara N, Pease A, Ranasinha S, et al. Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016. Sci Rep. 2018;8(1):7846.
   PubMed Web of Science ®Google Scholar
• Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811–831.
   PubMed Web of Science ®Google Scholar
• Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. WJD. 2017;8(4):120–129.
   Web of Science ®Google Scholar
• Guerci B, Chanan N, Kaur S, et al. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther. 2019;10(2):437–449.
   PubMed Web of Science ®Google Scholar
• Burrell A, Wong P, Ollendorf D, et al. PHP46 defining compliance/adherence and persistence: ISPOR Special Interest Working Group. Value Health. 2005;8(6):A194–A95.
   Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.
   PubMed Web of Science ®Google Scholar
• Bell KF, Cappell K, Liang M, et al. Comparing medication adherence and persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or sulfonylureas. Am Health Drug Benefits. 2017;10(4):165–174.
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. PPA. 2017;11:1103–1117.
   Web of Science ®Google Scholar
• Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604–609.
   PubMed Web of Science ®Google Scholar
• Jha AK, Aubert RE, Yao J, et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). 2012;31(8):1836–1846.
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958–2971.
   PubMed Web of Science ®Google Scholar
• Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5(1):225–242.
   PubMed Web of Science ®Google Scholar
• Iglay K, Cartier SE, Rosen VM, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31(7):1283–1296.
   PubMed Web of Science ®Google Scholar
• Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653–1664.e1.
   PubMed Web of Science ®Google Scholar
• Koyanagi K, Kubota T, Kobayashi D, et al. Prescription factors associated with medication non-adherence in Japan assessed from leftover drugs in the SETSUYAKU-BAG campaign: focus on oral antidiabetic drugs. Front Pharmacol. 2016;7:212.
   PubMed Web of Science ®Google Scholar
• Patel BD, Ghate MD. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014;74:574–605.
   PubMed Web of Science ®Google Scholar
• Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Kato H, Kisanuki K, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9(3):e025806.
   PubMed Web of Science ®Google Scholar
• Kato D, Ryu H, Matsumoto T, et al. Building primary care in Japan: literature review. J Gen Fam Med. 2019;20(5):170–179.
   PubMed Web of Science ®Google Scholar
• Wake M, Oh A, Onishi Y, et al. Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan. Atherosclerosis. 2019;282:19–28.
   PubMed Web of Science ®Google Scholar
• Fukuda H, Mizobe M. Impact of nonadherence on complication risks and healthcare costs in patients newly-diagnosed with diabetes. Diabetes Res Clin Pract. 2017;123:55–62.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87.
   PubMed Web of Science ®Google Scholar
• Feldman BS, Cohen-Stavi CJ, Leibowitz M, et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. PLoS One. 2014;9(9):e108145.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Kato H, Kisanuki K, et al. Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):869–878.
   PubMed Web of Science ®Google Scholar
• Witticke D, Seidling HM, Klimm HD, et al. Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence. 2012;6:679–684.
   PubMed Web of Science ®Google Scholar
• Meguro S, Matsui S, Itoh H. Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial. Curr Med Res Opin. 2019;35:2071–2078.
   PubMed Web of Science ®Google Scholar
• Keil R, Wasserbauer M, Zadorova Z, et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol. 2018;53(4):459–465.
   PubMed Web of Science ®Google Scholar
• Goette A, Hammwöhner M. How important it is for therapy adherence to be once a day? Eur Heart J Suppl. 2016;18(suppl I):I7–I12.
   Web of Science ®Google Scholar
• Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95(1):68–71.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Tunceli K, Yang JC, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Ther. 2015;6(1):75–84.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Hayakawa K, Oshima H. [Drug compliance of bisphosphonate in Japan: cohort study of bisphosphonate in a private clinic]. Osteoporosis Japan. 2009;17:252–255.
   Google Scholar
• Suzuki K, Hasegawa K, Watanabe M. Efficacy and patient satisfaction of dipeptidyl peptidase-4 inhibitor after switching from once-daily DPP-4 inhibitor to once-weekly regimen. J Clin Med Res. 2018;10(8):641–647.
   PubMedGoogle Scholar
• Ito H, Ando S, Tsugami E, et al. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. Diabetes Res Clin Pract. 2019;153:41–48.
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–1224.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
   PubMed Web of Science ®Google Scholar
• Lloyd CE, Mughal S, Roy T, et al. What factors influence concordance with medications? Findings from the UK Asian Diabetes study. Diabet Med. 2014;31(12):1600–1609.
   PubMed Web of Science ®Google Scholar
• Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care. 2011;34(Supplement_2):S231–S5.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. [National Health and Nutrition Survey]. 2017. [cited 2019 Nov 4]. Available from: https://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html.
   Google Scholar